The Guardian RT System records as many as 864 glucose readings during a three-day period using a disposable glucose sensor that connects to a transmitter and communicates to a monitor using radio frequency. The sensor measures glucose in the interstitial fluid found between the body's cells, and is typically discarded and replaced by the patient after three days of use. Glucose measurements are relayed every five minutes from the transmitter to the monitor, which displays the glucose values on its screen. Alarm thresholds can be preset to alert patients to potentially dangerous glucose levels. Trend reports and charts can be viewed after data is downloaded to a computer using therapy management software and a docking station.

The system is calibrated twice a day (every 12 hours) by entering a glucose measurement from a standard blood glucose meter into the Guardian RT's monitor. Patients can make self-management decisions after confirming with a fingerstick measurement.

The Guardian RT system is indicated for use in patients 18 years and older. It can be used by type 1 and type 2 diabetes patients who desire better glucose control to improve their health and quality of life. More information about the system can be accessed at www.minimed.com/guardianrt.

About Medtronic Diabetes

Medtronic Diabetes (www.minimed.com) is the world leader in pump therapy and continuous glucose monitoring. The company's products include external insulin pumps, related disposable products, and continuous glucose monitoring systems.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 29, 2005. Actual results may differ materially from anticipated results